Posted: May 6, 2024
-Contributed by Abi Kasberg, PhD Attending my first Advanced Technologies & Treatments for Diabetes (ATTD) conference in Florence, Italy this March was a treat for the mind (and palate). Being new to the diabetes space, it was thrilling to learn about the latest insights and advancements that are being made in diabetes research to improve…
Posted: October 24, 2023
-Contributed by Abi Kasberg, PhD Changes have arrived to the field of hepatic steatosis! In efforts to destigmatize and enhance the identification of steatotic liver diseases, several worldwide governing bodies (AASLD, EASL, and ALEH) recently came together to form a multi-stage Delphi panel that assessed, edited, and published changes to the standard nomenclature and diagnostic…
Posted: April 19, 2023
-Contributed by Abi Kasberg, PhD High levels of enthusiasm and excitement were shared at this year’s NASH-TAG meeting in Deer Valley, Utah, regarding the future of the NASH landscape. This was in large part due to the announcement of positive data from two phase 3 clinical trials for new NASH drugs: Madrigal’s Resmetirom and Intercept’s…
Posted: April 19, 2023
-Olivia Stricker, PhD Meetings are back baby! This was the first event that I have been to since the pandemic where it felt 100% back to normal. It was great to get back to it and have others there to get back to it with. In heading to Nashville, DiaPharma/I was in search of answers…
Posted: January 3, 2023
– Olivia Stricker, PhD and Commercial Business Development Manager at DiaPharma Group I recently attended the AASLD Emerging Topics in Alcohol-associated Liver Disease conference in Philadelphia, PA. Although I had been researching clinical practices in alcohol-associated liver disease (ALD) for the past 6 months, I quickly realized how limited my perspective was from only consuming…
Posted: December 21, 2022
-Contributed by Abi Kasberg, PhD After recently attending the AASLD Emerging Topics in Alcohol-associated Liver Disease conference, it quickly came to my attention the complexities and challenges that are faced while treating alcohol- associated liver diseases (ALD). For one, current treatment options for ALD are incredibly limited. ALD therapies are disputed in effectiveness and can…
Posted: May 5, 2022
-Contributed by Abi Kasberg, PhD The immune checkpoint is a vital regulatory component that prevents the immune system from targeting healthy cells or developing autoimmunity. It does so via immunoreceptors that suppress T cell activity in mechanisms that protect normal, healthy cells from destruction. However, prolonged expression of immune checkpoint proteins can lead to T…
Posted: September 27, 2021
A Trio of Biomarkers: A Novel Multivariate Model to Detect DILI & Liver Damage -Contributed by Abi Kasberg, PhD While maybe underappreciated, Drug-induced liver injury (DILI) is a condition with significant impact on the medical world. DILI is the leading cause of acute liver failure and is frequently responsible for the termination and withdrawal of…
Posted: July 8, 2021
In vitro Liver Culture Systems to Investigate DILI Contributed by Abi Kasberg, PhD An important function of the liver is to concentrate and metabolize drugs and xenobiotics, which makes the liver vulnerable to tissue damage. Drug-induced Liver Injury (DILI) is the onset of liver damage caused by drugs, medications, or supplements. DILI is associated with…
Posted: September 3, 2020
– Contributed by Abi Kasberg, PhD The global pandemic caused by the coronavirus SARS-CoV-2 has captured the attention of researchers, medical professionals, governments, and nearly everyone worldwide. The scientific and medical communities are forming collaborations, gathering data, developing therapeutics, and communicating findings at a swift speed. Indeed, it can be a challenge to stay informed…